Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025
Randomized Phase Ib Clinical Trial of DB-020 Intratympanic Injections to Reduce High-Dose Cisplatin Ototoxicity.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A viscosity-tunable microgel-in-sol phase for localized inner ear delivery of small hydrophilic drug.Materials today. Bio · 2026Article
- Article
- Acquired sensorineural hearing loss, oxidative stress, and microRNAs.Neural regeneration research · 2025Article
- Early-Phase Trials inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Unveiling the Role of Oxidative Stress in Cochlear Hair Cell Death: Prospective Phytochemical Therapeutics against Sensorineural Hearing Loss.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluated DB-020, a formulation of thiosulfate for intratympanic (IT) injection, in patients receiving high-dose cisplatin chemotherapy.
methodsThis randomized phase Ib clinical trial enrolled patients older than 18 years from five centers in Australia and the United States scheduled for at least three cycles of cisplatin and total cumulative exposure of ≥280 mg/m
resultsTwenty-two patients with a median age of 55.1 years were randomly assigned and received a mean total cumulative cisplatin dose of 255 mg/m
conclusionDB-020 IT injections were tolerated by patients and showed meaningful reductions in cisplatin ototoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.